Literature DB >> 6438290

Myopathy and growth failure in debrancher enzyme deficiency: improvement with high-protein nocturnal enteral therapy.

A E Slonim, R A Coleman, W S Moses.   

Abstract

Seven patients with debrancher enzyme deficiency and childhood or adolescent onset myopathy, four of whom also had growth failure, received long-term treatment consisting of high-protein enteral infusion overnight and high-protein feeds during the day for periods varying from 8 to 42 months. All patients demonstrated improvement in physical activity and endurance. Improvement in muscle strength was documented in five patients, with reversal of myopathic EMG patterns to normal in two patients and reversal of abnormal ECG findings to normal in one patient. All four patients with growth failure showed dramatic improvement in growth rates. This positive response to high-protein enteral therapy supports the concept that myopathy in debrancher enzyme deficiency is at least partly the result of reversible muscle amino acid depletion.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6438290     DOI: 10.1016/s0022-3476(84)80075-x

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  16 in total

1.  Cardiac Pathology in Glycogen Storage Disease Type III.

Authors:  S L Austin; A D Proia; M J Spencer-Manzon; J Butany; S B Wechsler; P S Kishnani
Journal:  JIMD Rep       Date:  2012-01-31

2.  Heart Failure Due to Severe Hypertrophic Cardiomyopathy Reversed by Low Calorie, High Protein Dietary Adjustments in a Glycogen Storage Disease Type IIIa Patient.

Authors:  Christiaan P Sentner; Kadir Caliskan; Wim B Vletter; G Peter A Smit
Journal:  JIMD Rep       Date:  2011-12-13

Review 3.  Glycogen storage disease: recommendations for treatment.

Authors:  J Fernandes; J V Leonard; S W Moses; M Odièvre; M di Rocco; J Schaub; G P Smit; K Ullrich; P Durand
Journal:  Eur J Pediatr       Date:  1988-04       Impact factor: 3.183

4.  Dietary Management of the Glycogen Storage Diseases: Evolution of Treatment and Ongoing Controversies.

Authors:  Katalin M Ross; Iris A Ferrecchia; Kathryn R Dahlberg; Monika Dambska; Patrick T Ryan; David A Weinstein
Journal:  Adv Nutr       Date:  2020-03-01       Impact factor: 8.701

5.  Uncooked cornstarch treatment for hepatic phosphorylase kinase deficiency.

Authors:  A Nakai; Y Shigematsu; T Takano; Y Kikawa; M Sudo
Journal:  Eur J Pediatr       Date:  1994-08       Impact factor: 3.183

6.  Different clinical aspects of debrancher deficiency myopathy.

Authors:  S Kiechl; U Kohlendorfer; C Thaler; D Skladal; M Jaksch; B Obermaier-Kusser; J Willeit
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

7.  Cardiomyopathy of glycogen storage disease type III.

Authors:  J S Carvalho; E E Matthews; J V Leonard; J Deanfield
Journal:  Heart Vessels       Date:  1993       Impact factor: 2.037

8.  Clinical, biochemical and genetic features of glycogen debranching enzyme deficiency.

Authors:  S Lucchiari; D Santoro; S Pagliarani; G P Comi
Journal:  Acta Myol       Date:  2007-07

9.  Reversal of glycogen storage disease type IIIa-related cardiomyopathy with modification of diet.

Authors:  A I Dagli; R T Zori; H McCune; T Ivsic; M K Maisenbacher; D A Weinstein
Journal:  J Inherit Metab Dis       Date:  2009-03-30       Impact factor: 4.982

Review 10.  Dietary management in glycogen storage disease type III: what is the evidence?

Authors:  Terry G J Derks; G Peter A Smit
Journal:  J Inherit Metab Dis       Date:  2014-08-28       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.